Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Paxil Pediatric Safety Concerns Have No Effect On Adult Use, FDA Says

Executive Summary

FDA is reassuring adult users about the safety of GlaxoSmithKline's Paxil in light of reports of an increased risk of suicidal thoughts in pediatric patients taking paroxetine
Advertisement

Related Content

GSK Faces New York Suit Over Paxil: Publish Or Punish?
GSK Faces New York Suit Over Paxil: Publish Or Punish?
Antidepressant Suicide Data To Be Evaluated For FDA By Columbia University
Antidepressant Suicide Data To Be Evaluated For FDA By Columbia University
Mass. Medicaid Holds Line Against GSK Line Extensions
Mass. Medicaid Holds Line Against GSK Line Extensions
FDA Expands Pediatric Suicidality Caution To Antidepressants Beyond Paxil
FDA Expands Pediatric Suicidality Caution To Antidepressants Beyond Paxil
GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.
GSK Discussing Paxil Pediatric Suicide Link With FDA; Label Change In U.K.
Advertisement
UsernamePublicRestriction

Register

PS042007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel